ES2748397T3 - Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario - Google Patents

Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario Download PDF

Info

Publication number
ES2748397T3
ES2748397T3 ES15175155T ES15175155T ES2748397T3 ES 2748397 T3 ES2748397 T3 ES 2748397T3 ES 15175155 T ES15175155 T ES 15175155T ES 15175155 T ES15175155 T ES 15175155T ES 2748397 T3 ES2748397 T3 ES 2748397T3
Authority
ES
Spain
Prior art keywords
patient
markers
ovarian cancer
marker
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15175155T
Other languages
English (en)
Spanish (es)
Inventor
Richard Moore
Elizabeth Somers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Diagnostics Inc
Original Assignee
Fujirebio Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Diagnostics Inc filed Critical Fujirebio Diagnostics Inc
Application granted granted Critical
Publication of ES2748397T3 publication Critical patent/ES2748397T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
ES15175155T 2006-01-04 2007-01-04 Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario Active ES2748397T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04

Publications (1)

Publication Number Publication Date
ES2748397T3 true ES2748397T3 (es) 2020-03-16

Family

ID=38256906

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15175155T Active ES2748397T3 (es) 2006-01-04 2007-01-04 Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario
ES15175154.2T Active ES2650244T3 (es) 2006-01-04 2007-01-04 Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres endometriales y uterinos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15175154.2T Active ES2650244T3 (es) 2006-01-04 2007-01-04 Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres endometriales y uterinos

Country Status (7)

Country Link
US (8) US20080020473A1 (https=)
EP (6) EP2982761B1 (https=)
JP (3) JP5221381B2 (https=)
CN (3) CN101473041B (https=)
ES (2) ES2748397T3 (https=)
PL (1) PL2982761T3 (https=)
WO (2) WO2007081767A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5604100A (en) * 1999-06-09 2000-12-28 Moltech Corporation Methods of preparing a microporous article
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
EP2363711A1 (en) * 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
CN101802014A (zh) * 2007-03-09 2010-08-11 三路影像公司 He4单克隆抗体和它们的使用方法
JP5144742B2 (ja) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド 乳がんの評価のためのｈｅ４の使用
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US20130224772A1 (en) * 2010-08-26 2013-08-29 University Of Washington Through Its Center For Commercialization Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
JP5887364B2 (ja) 2011-02-17 2016-03-16 フジレビオ ダイアグノスティックス インコーポレイテッド ＨＥ４ａの測定のための組成物および使用方法
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
EP4139289A1 (en) 2020-04-21 2023-03-01 University of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
US20240385195A1 (en) * 2022-04-08 2024-11-21 Ajou University Industry-Academic Cooperation Foundation Peptide for detecting ca125 and use thereof
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
DE60028361T2 (de) 1999-02-26 2007-05-10 Pacific Northwest Research Institute, Seattle Verfahren und zusammensetzungen zur karzinomdiagnose
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
NZ562192A (en) * 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
JP2006515065A (ja) * 2002-08-16 2006-05-18 ディシジョン バイオマーカーズ インコーポレイテッド 蛍光配列の読み取り
AU2003290773A1 (en) * 2003-02-05 2004-09-06 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
DK1633784T3 (da) * 2003-05-09 2011-10-24 Diadexus Inc OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
CA2597271A1 (en) * 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
JP5159619B2 (ja) * 2005-06-22 2013-03-06 ザ・ジョンズ・ホプキンス・ユニバーシティ 卵巣癌のバイオマーカー：ｃｔａｐ３関連タンパク質
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用

Also Published As

Publication number Publication date
JP2009521953A (ja) 2009-06-11
EP1969136A4 (en) 2009-04-15
JP5164855B2 (ja) 2013-03-21
EP3026119A1 (en) 2016-06-01
JP5221381B2 (ja) 2013-06-26
US20080020473A1 (en) 2008-01-24
US20200292549A1 (en) 2020-09-17
CN101460630A (zh) 2009-06-17
JP5711196B2 (ja) 2015-04-30
ES2650244T3 (es) 2018-01-17
HK1219514A1 (en) 2017-04-07
WO2007081768A3 (en) 2008-04-24
US20240288434A1 (en) 2024-08-29
US20240133889A1 (en) 2024-04-25
JP2013050457A (ja) 2013-03-14
WO2007081767A2 (en) 2007-07-19
CN101473041A (zh) 2009-07-01
EP2423321A2 (en) 2012-02-29
CN101460630B (zh) 2016-08-10
US20240230652A9 (en) 2024-07-11
EP1969136A2 (en) 2008-09-17
US20200182878A1 (en) 2020-06-11
EP2982761A1 (en) 2016-02-10
WO2007081768A2 (en) 2007-07-19
EP2420576A3 (en) 2012-03-14
US20180156805A1 (en) 2018-06-07
PL2982761T3 (pl) 2018-03-30
EP2423321A3 (en) 2012-03-14
EP2420576A2 (en) 2012-02-22
US20070286865A1 (en) 2007-12-13
JP2009522578A (ja) 2009-06-11
EP2982761B1 (en) 2017-10-04
EP1846768A4 (en) 2009-04-08
EP1846768A2 (en) 2007-10-24
CN106124765A (zh) 2016-11-16
US20180180620A1 (en) 2018-06-28
WO2007081767A3 (en) 2008-04-24
CN101473041B (zh) 2017-11-14
EP3026119B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
ES2748397T3 (es) Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario
ES2411921T3 (es) Uso de HE4 para la evaluación de cánceres de mama
HK1225411B (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1225411A (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1225411A1 (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1166109A (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
HK1219514B (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1166110A (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1136630B (en) Use of he4 for assessment of breast cancers